Clinical Trial Update: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and tolerability of a 3-month salbutamol inhaler treatment in adults with asthma, comparing two propellant formulations (HFA-152a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Salbutamol inhaler (salbutamol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED